218 related articles for article (PubMed ID: 29520928)
1. PBOV1 as a potential biomarker for more advanced prostate cancer based on protein and digital histomorphometric analysis.
Carleton NM; Zhu G; Gorbounov M; Miller MC; Pienta KJ; Resar LMS; Veltri RW
Prostate; 2018 May; 78(7):547-559. PubMed ID: 29520928
[TBL] [Abstract][Full Text] [Related]
2. Characterization of RNA-Binding Motif 3 (RBM3) Protein Levels and Nuclear Architecture Changes in Aggressive and Recurrent Prostate Cancer.
Carleton NM; Zhu G; Miller MC; Davis C; Kulkarni P; Veltri RW
Cancer Rep (Hoboken); 2020 Jun; 3(3):e1237. PubMed ID: 32587951
[TBL] [Abstract][Full Text] [Related]
3. TRPM4 protein expression in prostate cancer: a novel tissue biomarker associated with risk of biochemical recurrence following radical prostatectomy.
Berg KD; Soldini D; Jung M; Dietrich D; Stephan C; Jung K; Dietel M; Vainer B; Kristiansen G
Virchows Arch; 2016 Mar; 468(3):345-55. PubMed ID: 26590985
[TBL] [Abstract][Full Text] [Related]
4. Prostatectomy-based validation of combined urine and plasma test for predicting high grade prostate cancer.
Albitar M; Ma W; Lund L; Shahbaba B; Uchio E; Feddersen S; Moylan D; Wojno K; Shore N
Prostate; 2018 Mar; 78(4):294-299. PubMed ID: 29315679
[TBL] [Abstract][Full Text] [Related]
5. Multiparametric MRI in detection and staging of prostate cancer.
Boesen L
Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
[TBL] [Abstract][Full Text] [Related]
6. Evaluation and characterization of anti-RalA autoantibody as a potential serum biomarker in human prostate cancer.
Li J; Dai L; Lei N; Xing M; Li P; Luo C; Casiano CA; Zhang JY
Oncotarget; 2016 Jul; 7(28):43546-43556. PubMed ID: 27286458
[TBL] [Abstract][Full Text] [Related]
7. Prostate specific G protein coupled receptor is associated with prostate cancer prognosis and affects cancer cell proliferation and invasion.
Cao W; Li F; Yao J; Yu J
BMC Cancer; 2015 Nov; 15():915. PubMed ID: 26582057
[TBL] [Abstract][Full Text] [Related]
8. p300 (histone acetyltransferase) biomarker predicts prostate cancer biochemical recurrence and correlates with changes in epithelia nuclear size and shape.
Isharwal S; Miller MC; Marlow C; Makarov DV; Partin AW; Veltri RW
Prostate; 2008 Jul; 68(10):1097-104. PubMed ID: 18459105
[TBL] [Abstract][Full Text] [Related]
9. The Proteome of Primary Prostate Cancer.
Iglesias-Gato D; Wikström P; Tyanova S; Lavallee C; Thysell E; Carlsson J; Hägglöf C; Cox J; Andrén O; Stattin P; Egevad L; Widmark A; Bjartell A; Collins CC; Bergh A; Geiger T; Mann M; Flores-Morales A
Eur Urol; 2016 May; 69(5):942-52. PubMed ID: 26651926
[TBL] [Abstract][Full Text] [Related]
10. PRL‑3 increases the aggressive phenotype of prostate cancer cells in vitro and its expression correlates with high-grade prostate tumors in patients.
Edwards DR; Moroz K; Zhang H; Mulholland D; Abdel-Mageed AB; Mondal D
Int J Oncol; 2018 Feb; 52(2):402-412. PubMed ID: 29207031
[TBL] [Abstract][Full Text] [Related]
11. Expression of CDX2 in benign tissue and adenocarcinoma of the prostate.
Herawi M; De Marzo AM; Kristiansen G; Epstein JI
Hum Pathol; 2007 Jan; 38(1):72-8. PubMed ID: 16949907
[TBL] [Abstract][Full Text] [Related]
12. Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
Debiais-Delpech C; Godet J; Pedretti N; Bernard FX; Irani J; Cathelineau X; Cussenot O; Fromont G
Urol Oncol; 2014 May; 32(4):426-32. PubMed ID: 24332637
[TBL] [Abstract][Full Text] [Related]
13. Differential tissue expression of extracellular vesicle-derived proteins in prostate cancer.
Duijvesz D; Rodriguez-Blanco G; Hoogland AM; Verhoef EI; Dekker LJ; Roobol MJ; van Leenders GJLH; Luider TM; Jenster G
Prostate; 2019 Jun; 79(9):1032-1042. PubMed ID: 31018022
[TBL] [Abstract][Full Text] [Related]
14. PPM1D as a novel biomarker for prostate cancer after radical prostatectomy.
Jiao L; Shen D; Liu G; Jia J; Geng J; Wang H; Sun Y
Anticancer Res; 2014 Jun; 34(6):2919-25. PubMed ID: 24922655
[TBL] [Abstract][Full Text] [Related]
15. Negative LC3b immunoreactivity in cancer cells is an independent prognostic predictor of prostate cancer specific death.
Mortezavi A; Salemi S; Rupp NJ; Rüschoff JH; Hermanns T; Poyet C; Randazzo M; Simon HU; Moch H; Sulser T; Wild P; Eberli D
Oncotarget; 2017 May; 8(19):31765-31774. PubMed ID: 28423666
[TBL] [Abstract][Full Text] [Related]
16. High stroma-derived WNT5A is an indicator for low-risk prostate cancer.
Kisel W; Conrad S; Borkowetz A; Furesi G; Füssel S; Sommer U; Rauner M; Thomas C; Baretton GB; Schaser KD; Hofbauer C; Hofbauer LC
FEBS Open Bio; 2021 Apr; 11(4):1186-1194. PubMed ID: 33639039
[TBL] [Abstract][Full Text] [Related]
17. The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation.
Ouellet V; Aprikian A; Bergeron A; Brimo F; Bristow RG; Chevalier S; Drachenberg D; Fazli L; Fleshner NE; Gleave M; Karakiewicz P; Klotz L; Lacombe L; Lattouf JB; van der Kwast T; Squire JA; Latour M; Trudel D; Mes-Masson AM; Saad F
BMC Urol; 2018 Sep; 18(1):78. PubMed ID: 30200929
[TBL] [Abstract][Full Text] [Related]
18. The value of ADC, T2 signal intensity, and a combination of both parameters to assess Gleason score and primary Gleason grades in patients with known prostate cancer.
Nowak J; Malzahn U; Baur AD; Reichelt U; Franiel T; Hamm B; Durmus T
Acta Radiol; 2016 Jan; 57(1):107-14. PubMed ID: 25505225
[TBL] [Abstract][Full Text] [Related]
19. Expression of prostate stem cell antigen (PSCA) in prostate cancer: a tissue microarray study of Iranian patients.
Taeb J; Asgari M; Abolhasani M; Farajollahi MM; Madjd Z
Pathol Res Pract; 2014 Jan; 210(1):18-23. PubMed ID: 24183365
[TBL] [Abstract][Full Text] [Related]
20. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
